This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Compugen Discloses Predictive Structural Biology Infrastructure Platform For Enhanced Discovery Of Novel Drugs

Compugen Ltd. ( NASDAQ: CGEN) announced today the ongoing development of a Predictive Structural Biology (PSB) Infrastructure Platform designed to computationally identify the functional interaction sites of proteins, which are of substantial importance for the rational design of novel drugs. The current application of this new infrastructure capability aims at enhanced discovery of functional monoclonal antibodies in cancer and immunology, Compugen’s core areas of focus.

Protein interactions are central to key biological functions, and thus the therapeutic applications of modulating such interactions are wide-ranging and of high industry interest. In general, modulation occurs when the drug binds to the protein's functional interaction sites. However, the correct identification of functional interaction sites of proteins has in many cases proven to be challenging. Accurately predicting functional interaction sites would therefore be of great help in the design of novel drugs.

In the area of therapeutic antibodies, which represents one of the fastest growing segments in pharmaceuticals, there have been important advances in multiple technologies developed for accelerating therapeutic antibody discovery. However, generating antibodies having the required biological and therapeutic functions remains very difficult. The current application of the PSB Infrastructure Platform targets this problem.

The development of this new infrastructure platform relies heavily on the integration of capabilities previously developed for Compugen’s PPI Blockers Discovery Platform, such as computational prediction of protein-protein interaction sites, certain protein engineering know-how, and, specifically for the therapeutic antibody application, a molecular analysis of antibody-antigen interactions.

Dr. Anat Cohen-Dayag, president and CEO of Compugen, stated, “The flexibility of the PSB Infrastructure Platform creates the potential to provide a wide range of drug discovery capabilities and applications, and therefore it is expected to be an important addition to Compugen’s unique predictive infrastructure.”

Dr. Cohen-Dayag continued, “The current application of this new capability is being designed not only to enhance the discovery of functional therapeutic monoclonal antibodies that modulate Compugen-discovered novel targets, but also to allow us to generate monoclonal antibodies against additional targets, such as those that have to date proven refractory to antibody targeting attempts. The uniqueness of the current application is its focus on functional protein regions, thereby increasing the likelihood of generating functional antibodies with the desired therapeutic activity. Furthermore, future modifications of the current application may enable us to introduce selected specificities to a given antibody in a predictable manner.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs